People with ulcerative colitis live, on average, about five years less than people without it. A 2023 review in JAMA estimated life expectancy at roughly 80.5 years for women and 76.7 years for men with the disease, compared to about 85 and 82 years respectively in the general population.1JAMA. Ulcerative Colitis in Adults: A Review That five-year gap, though, is an average across all patients, and the actual picture is more encouraging for many people than that number suggests. Several large population studies have found that overall mortality in ulcerative colitis barely differs from the general population, and certain specific risk factors do most of the heavy lifting behind the shortfall.
How Close to Normal Is Survival, Really?
The five-year gap sounds alarming, but it is pulled heavily by a subset of patients who face serious complications. When researchers track large groups of people with ulcerative colitis over time, the mortality difference from the general population is often small or statistically indistinguishable. A well-known Danish cohort study followed patients for decades and found 261 deaths where about 249 would have been expected in a matched general population, a difference that was not statistically significant.2PubMed. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County A more recent population-based study covering the era of biologic medications found virtually no excess mortality in ulcerative colitis patients compared to matched controls.3Journal of Crohn’s and Colitis. All-cause and cause-specific mortality in inflammatory bowel disease across the biologic era: a population-based matched cohort study
A meta-analysis that pooled multiple population studies did find a modestly elevated overall mortality for ulcerative colitis, with a summary standardized mortality ratio of about 1.19, meaning roughly a 19 percent higher death rate than expected.4PubMed Central. Crohn’s Disease and Ulcerative Colitis Are Associated With Elevated Standardized Mortality Ratios: A Meta-Analysis That is real but modest, and it is driven mostly by specific causes rather than a general decline in health. The studies that show the smallest gap tend to be the most recent, which reflects how much modern treatments have improved outcomes. So the honest answer is: if your disease is well managed with current therapies, your survival odds are close to someone without the condition. The gap widens when complications arise, treatment is delayed, or certain co-existing conditions develop.
What Actually Drives the Mortality Gap
The meta-analysis just described broke down the causes of death in ulcerative colitis and found some surprises. Mortality from colorectal cancer, lung disease, and nonalcoholic liver disease was elevated. Mortality from cardiovascular disease was actually decreased.4PubMed Central. Crohn’s Disease and Ulcerative Colitis Are Associated With Elevated Standardized Mortality Ratios: A Meta-Analysis That cardiovascular finding may seem counterintuitive, since chronic inflammation generally raises heart risk, and people with inflammatory bowel disease do face a higher risk of blood clots. Thrombotic events occur at roughly 1.5 to 4 times the rate seen in the general population, especially during active disease flares, pregnancy, and the postpartum period.5GastroenterologÃa y HepatologÃa (English Edition). Inflammatory bowel disease and the risk of cardiovascular diseases The lower cardiovascular mortality in the meta-analysis may reflect competing causes of death, protective effects of anti-inflammatory medications, or simply that people with a chronic illness see doctors more often and have risk factors caught earlier. Researchers are still sorting this out.
The liver disease connection is largely about primary sclerosing cholangitis, a condition discussed in more detail below. The lung disease link is less well understood but may involve both chronic medication effects and shared immune pathways. The point is that ulcerative colitis does not shorten life through a single pathway. Instead, a handful of specific complications account for most of the excess risk, and several of them are detectable and manageable with proper monitoring.
Colorectal Cancer Risk
Colorectal cancer is probably the most widely known long-term risk of ulcerative colitis, and the numbers are not trivial. The estimated cumulative risk is about 2 percent after 10 years of disease, 8 percent after 20 years, and 18 percent after 30 years.6PubMed Central. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies Risk factors include how much of the colon is involved, how long the disease has been present, severity of inflammation, a family history of colorectal cancer, and whether the patient also has primary sclerosing cholangitis.
The encouraging news is that population-based studies from the past couple of decades suggest the risk has been decreasing, likely because of better surveillance colonoscopy programs and more effective medications that keep inflammation in check. The crude annual incidence of colorectal cancer in ulcerative colitis now ranges from about 0.06 to 0.16 percent per year.6PubMed Central. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies Regular surveillance colonoscopies are the main tool for catching dysplasia or early-stage cancer, and guidelines generally recommend beginning screening colonoscopies about 8 to 10 years after diagnosis for patients with extensive colitis.
Primary Sclerosing Cholangitis Changes the Picture
A minority of ulcerative colitis patients also develop primary sclerosing cholangitis (PSC), a progressive disease of the bile ducts that significantly worsens the outlook. In a Japanese cohort, 10-year survival from UC diagnosis was about 77 percent in patients who also had PSC, compared to over 99 percent in those with ulcerative colitis alone.7PLoS ONE. Clinical characteristics and outcomes of primary sclerosing cholangitis and ulcerative colitis in Japanese patients A large propensity-matched cohort study found that UC patients with PSC had nearly double the risk of death compared to UC patients without it.8PubMed Central. Primary Sclerosing Cholangitis Worsens Prognosis in Patients With Inflammatory Bowel Disease: A Propensity-Matched Cohort Study
PSC also sharply raises colorectal cancer risk beyond the already elevated baseline. In one study, about 36 percent of PSC-UC patients developed colon neoplasia, compared to much lower rates in patients with ulcerative colitis alone.9Gastroenterology Report. Comparison of outcomes for patients with primary sclerosing cholangitis associated with ulcerative colitis and Crohn’s disease PSC patients also face a risk of cholangiocarcinoma, a cancer of the bile ducts. For anyone with both conditions, more frequent cancer surveillance and closer liver monitoring are standard practice. PSC is relatively uncommon, affecting a small percentage of all UC patients, but it punches well above its weight in terms of impact on survival, and it is one reason the average life expectancy numbers look worse than most individual patients will experience.
Age at Diagnosis Makes a Difference
People diagnosed with ulcerative colitis later in life face a tougher road than those diagnosed young. A population-based study of patients diagnosed at age 60 or older found that elderly-onset UC was associated with a roughly 50 percent higher rate of death compared to age-matched people without inflammatory bowel disease.10American Journal of Gastroenterology. Mortality in Elderly Onset Ulcerative Colitis: A Population-Based Cohort Study Older patients are more vulnerable to infections like cytomegalovirus and Clostridioides difficile, and they face higher rates of colorectal cancer and all-cause mortality than younger-onset patients.11Journal of Crohn’s and Colitis. Natural History of Elderly-onset Ulcerative Colitis: Results from a Territory-wide Inflammatory Bowel Disease Registry
Part of this is simply because older adults have less physiological reserve and more co-existing health problems. But the disease itself can also behave differently: elderly patients may respond less well to certain medications, and clinicians sometimes hesitate to use aggressive immunosuppressive therapies in older patients due to infection concerns. A Korean cohort study found that disease extent and colectomy rates were actually comparable between elderly-onset and younger-onset patients, suggesting the disease course itself may not always be more severe.12PubMed Central. Clinical Characteristics and Long-term Prognosis of Elderly-Onset Ulcerative Colitis in a Population-Based Cohort in the Songpa-Kangdong District of Seoul, Korea The worse outcomes in older patients likely reflect the interaction between chronic inflammatory disease and aging biology rather than more aggressive colitis per se.
For younger patients, especially children, the disease can be extensive at diagnosis but often follows a manageable trajectory with modern treatment. A Korean pediatric study found that the cumulative colectomy rate was lower than in many Western cohorts, and the overall clinical course was relatively benign with proper follow-up.13PubMed Central. Clinical Characteristics and Long-term Outcomes of Pediatric Ulcerative Colitis: A Single-Center Experience in Korea
How Surgery Affects Survival
Removing the colon sounds drastic, and it is a major decision, but the data on long-term outcomes after colectomy are reassuring. A large English record-linkage study found that three years after elective colectomy, mortality was just 3.7 percent, compared to 13.6 percent in patients admitted for ulcerative colitis who did not have surgery and 13.2 percent in those who had emergency colectomy. After about two months following elective surgery, mortality returned to that of the general population for equivalent age.14BMJ. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn’s disease: record linkage studies
Timing matters enormously. Emergency colectomy carries far higher risks than planned surgery. In a Danish study, 30-day mortality after elective colectomy for ulcerative colitis was under 1 percent, compared to about 5 percent after emergency surgery.15BMJ Open. Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study When emergency colectomy was delayed rather than performed promptly, the situation worsened further. A study comparing early versus delayed emergency colectomy found that delay was associated with a mortality rate of about 20 percent compared to about 5 percent with early surgery, an 82 percent reduction in death odds when colectomy was done promptly.16PubMed Central. Outcomes for ulcerative colitis with delayed emergency colectomy are worse when controlling for preoperative risk factors
The implication is clear: colectomy is not a failure of treatment. For patients with refractory disease, dysplasia, or toxic colitis, planned surgery can actually normalize life expectancy. It is the emergency scenarios, especially delayed ones, where the danger concentrates. Toxic megacolon, a severe complication involving extreme dilation of the colon with systemic toxicity, is one of those emergencies that requires rapid multidisciplinary management to avoid fatal outcomes.17PubMed Central. Management of Severe Colitis and Toxic Megacolon
Treatment Choices and Medication Adherence
What medications you take, and whether you actually take them consistently, has a measurable effect on long-term outcomes. Prolonged use of corticosteroids, once the default for managing flares, is associated with higher death rates compared to newer biologic therapies. A study comparing anti-TNF therapy to prolonged corticosteroid use found that among UC patients, the annual death rate was about 23 per 1,000 treated patients on anti-TNF agents versus roughly 31 per 1,000 on prolonged steroids.18PubMed Central. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease Long-term steroid use carries its own set of health consequences, from bone loss to metabolic problems, that stack on top of the disease itself.19PubMed Central. Drug therapy for ulcerative colitis
Biologic agents are not risk-free either. Anti-TNF drugs can increase susceptibility to infections, and the risk rises further when biologics are combined with immunosuppressants or corticosteroids. There is also a possible link to lymphoma, particularly with combination therapy.20PubMed Central. Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases That said, current biological therapies are considered relatively safe overall, and the benefits of controlling inflammation generally outweigh the risks when used with appropriate screening and monitoring.21PubMed. The safety of biological pharmacotherapy for the treatment of ulcerative colitis
Medication adherence is arguably as important as which medication you are on. A systematic review found that the risk of flare in non-adherent patients was at least 3.65 times higher than in adherent patients, and adherent patients’ total annual healthcare costs were about 12.5 percent lower despite spending more on medications themselves.22PubMed. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares A Delphi consensus review estimated that non-adherence rates of 30 to 45 percent in IBD patients are linked to a fivefold higher relapse risk and up to 80 percent more hospitalizations.23Digestive and Liver Disease. Therapeutic adherence in inflammatory bowel disease: User guide from a multidisciplinary modified Delphi consensus Since uncontrolled inflammation is what drives both cancer risk and the need for emergency surgery, keeping flares to a minimum through consistent treatment is one of the most direct ways to protect long-term survival.
Lifestyle Factors That Move the Needle
Beyond medication, everyday health habits have a surprisingly strong association with mortality in ulcerative colitis. A large prospective study found that UC patients who maintained three or more healthy lifestyle factors had roughly a 76 percent lower risk of death compared to those with none.24PubMed Central. Healthy Lifestyle is Associated with Reduced Mortality in Patients with Inflammatory Bowel Diseases Even having just one or two healthy factors cut the risk substantially. The lifestyle factors studied included things like maintaining a healthy weight, not smoking, regular physical activity, and eating a balanced diet. A more recent analysis reinforced this, noting that favorable lifestyle choices may reduce mortality risk in IBD partly by improving metabolic health.25PubMed Central. Association of healthy lifestyle, metabolic alterations and lower mortality risk of IBD patients: a prospective cohort and mediation analysis
These are observational findings, and people who maintain healthy habits tend to differ from those who don’t in ways researchers cannot fully account for. Still, the size of the effect is hard to dismiss, and the direction is consistent with what we know about chronic inflammation and overall health. Smoking is particularly relevant: unlike Crohn’s disease, where smoking worsens the disease, the relationship with ulcerative colitis is more complex, but smoking damages nearly every other organ system and adds risk regardless. Exercise, diet, and weight management influence systemic inflammation, immune function, and mental health, all of which interact with ulcerative colitis.
Mental Health and the Disease Course
Depression and anxiety are common in ulcerative colitis, and they appear to do more than reduce quality of life. A longitudinal study of patients with moderate-to-severe UC found that while baseline anxiety and depression did not significantly affect rates of clinical remission or hospitalization overall, patients who had both conditions were more likely to experience multiple relapses.26PubMed Central. Anxiety and Depression Are Associated with Poor Long-term Quality of Life in Moderate-to-Severe Ulcerative Colitis: Results of a 3-Year Longitudinal Study of the MOSAIK Cohort Patients with depression also tended to use more corticosteroids, though the difference was not statistically significant in that study. The connection between psychological distress and disease activity may run partly through the gut microbiome: UC patients with depression and anxiety have been shown to have lower microbial diversity and different bacterial compositions than UC patients without these conditions.27PubMed Central. Depression and anxiety in patients with active ulcerative colitis: crosstalk of gut microbiota, metabolomics and proteomics
It is worth noting that medication non-adherence, discussed above, is itself strongly correlated with disability and difficult symptom management. Patients who struggled with managing bowel movements, who had ongoing rectal bleeding, or who dealt with joint inflammation were significantly more likely to stop taking their medications.28PubMed Central. Medication non-adherence in inflammatory bowel diseases is associated with disability Depression and practical difficulties with disease symptoms can create a feedback loop where patients stop treatment, flare more often, and lose further quality of life. Addressing mental health is not peripheral to managing ulcerative colitis. It is part of the core strategy for staying well.
Geographic and Demographic Disparities
Not everyone with ulcerative colitis faces the same odds. A U.S. study examining mortality trends found increasing IBD mortality nationally, with significant disparities by sex, race, ethnicity, and geography. Differences in access to specialty care and biologic therapy were identified as likely contributors to the gap.29PubMed Central. Who bears the brunt? Geographic, racial and ethnic disparities in mortality trends of inflammatory bowel disorders in the United States In practical terms, a person living in a rural area without easy access to a gastroenterologist, or someone without insurance coverage for biologic medications, faces a meaningfully different prognosis than someone with full access to modern care. The biology of the disease is the same, but what you can actually do about it varies widely depending on where and how you live.
This is one of the underappreciated factors behind the average life expectancy numbers. When a study reports a five-year gap, that average is shaped by people who received optimal care and people who did not, people in high-resource settings and people in lower-resource ones. For someone with good access to gastroenterology, biologics, and routine surveillance, the personal gap is likely smaller than the headline figure suggests.